#DiseaseLiteracyMonth #multiplesclerosis #SelmaBlair #motivational
Quantum BioPharma (NASDAQ: QNTM) receives FDA clearance to begin a Phase 2 trial of Lucid-MS, a first-in-class drug targeting demyelination in multiple sclerosis. Rodman & Renshaw initiates coverage with a Buy rating and $8 price target. #MultipleSclerosis #Biopharma
